TROD’s MedTech for Prostate Cancer Kills Tumor Cells with Radio Waves

11/01/2016 - 2 minutes

TROD Medical, the medical device company developing tools for focal ablation, today announced that it has received CE Mark Approval for its Encage device.

trod_medical_prostate_cancer_medtech_biotechEncage is a breakthrough in treatment for prostate cancer, one of the most common soft tissue cancers in the world with around 240,000 new cases every year in the US alone. As the lead Medtech product in question, it has the potential to reduce the risk of side effects commonly associated with current treatments, including erectile dysfunction (impotence), and urinary and fecal incontinence.

The Encage device therefore represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.

TROD Medical is a VC-backed company with two co-leads founded in 2006 by Andre Faure, Capricorn Venture Partners (Belgium) and Vesalius Biocapital (Luxembourg). The Company is headquartered in Leuven (Belgium) and has facilities in the Tampa Bay area (US), and Paris (France).

As Faure explained,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!